How Investors Are Reacting To Teva Pharmaceutical Industries (TEVA) Earnings Beat

What happened: Teva Pharmaceutical Industries reported Q3 2026 sales of US$4.4b with earnings that topped some analyst expectations, and management raised the 2026 outlook for key branded products AUSTEDO, AJOVY, UZEDY and WELTRUZA. Key numbers: Q3 2026 sales US$4.4b; Q3 Why it matters: The new U.S. biosimilars agreement with Samsung Bioepis on infliximab-abda and etanercept-ykro adds another revenue pillar and could shift the mix away from older generics. The halt of the Phase 2 TOPAS MSA study of emrusolmin after a futility analysis slightly raises execution risk around the R&D catalyst.

Teva Pharmaceutical Industries reported Q3 2026 sales of US$4.4b with earnings that topped some analyst expectations, and management raised the 2026 outlook for key branded products AUSTEDO, AJOVY, UZEDY and WELTRUZA.

The new U.S. biosimilars agreement with Samsung Bioepis on infliximab-abda and etanercept-ykro adds another revenue pillar and could shift the mix away from older generics. The halt of the Phase 2 TOPAS MSA study of emrusolmin after a futility analysis slightly raises execution risk around the R&D catalyst.